Apimeds Pharmaceuticals US (APUS) Cash & Equivalents (2023 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Cash & Equivalents for 4 consecutive years, with $116.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 1236.38% year-over-year to $116.7 million; the trailing twelve-month figure through Jun 2026 stood at $116.7 million (up 1236.38% YoY), and the FY2025 full-year result was $149.9 million, up 4338116.24% from the prior year.
• Cash & Equivalents retreated to $116.7 million in Q2 2026 per APUS's latest filing, from $149.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $149.9 million in Q4 2025 and bottomed at $3455.0 in Q4 2024.
• Historically, Cash & Equivalents has averaged $40.4 million across 4 years, with a median of $7.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 99.16% in 2024, then jumped 4338116.24% in 2025.
• Over 4 years, Cash & Equivalents stood at $410481.0 in 2023, then slumped by 99.16% to $3455.0 in 2024, then surged by 4338116.24% to $149.9 million in 2025, then fell by 22.12% to $116.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $116.7 million, $149.9 million, and $7.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.